Alan Hulme
Direttore/Membro del Consiglio presso Oncopeptides Incentive AB
Patrimonio netto: 121 380 $ in data 30/04/2024
Profilo
Alan Hulme is currently a Director at Oncopeptides Incentive AB and Techgen Corporate Development Ltd.
He previously served as Chairman at Oncopeptides AB from 2010 to 2018.
He also held positions as Chairman at Techgen International Ltd., Director at Quiatech AB, Mesophotonics Ltd., OLIGOvation AB, Principal at IDEXX Laboratories, Inc., and Principal at Affymetrix, Inc.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
ONCOPEPTIDES AB
0.22% | 29/08/2023 | 457 813 ( 0.22% ) | 121 380 $ | 30/04/2024 |
Posizioni attive di Alan Hulme
| Società | Posizione | Inizio |
|---|---|---|
| Oncopeptides Incentive AB | Direttore/Membro del Consiglio | - |
| Techgen Corporate Development Ltd. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Alan Hulme
| Società | Posizione | Fine |
|---|---|---|
| ONCOPEPTIDES AB | Presidente | 17/05/2018 |
Quiatech AB
 Quiatech AB Pharmaceuticals: MajorHealth Technology Quiatech AB develops and manufactures drugs. It is a research based company that develops enabling technologies for genetic analysis, molecular diagnostics, and gene-based therapeutics in the expanding market of DNA technologies that offer significant improvements in the quality of DNA microarray and other DNA oligonucleotide data. It has also developed a new modified RNA chemistry (Qt RNA Technology) utilizing a novel 2 protecting group on the RNA amidites, this development greatly improves the synthesis conditions, producing fully functional RNA at high yields. It is headquartered in Uppsala, Sweden. | Direttore/Membro del Consiglio | 30/08/2007 |
Techgen International Ltd.
 Techgen International Ltd. Miscellaneous Commercial ServicesCommercial Services Techgen International Ltd. provides financial advisory services. The private company is based in London, UK. | Presidente | - |
OLIGOvation AB
 OLIGOvation AB Miscellaneous Commercial ServicesCommercial Services OLIGOvation AB develops enabling technologies for genetic analysis, molecular diagnostics and gene-based therapeutics. It offers services in the market of DNA technologies that offer improvements in the quality of DNA microarray and other DNA oligonucleotide data. The company was founded in February, 2000 and is headquartered in Uppsala, Sweden. | Direttore/Membro del Consiglio | - |
Mesophotonics Ltd.
 Mesophotonics Ltd. Computer CommunicationsElectronic Technology Mesophotonics Ltd. develops photonic crystal devices and circuits. Its devices allows light to be bent, routed and processed at sub-millimeter scale. It offers multiple optical functions and systems to be implemented on a single silicon chip for production of integrated optical devices. The company was founded by Caterina Netti, Majd Zoorob, Simon Cox, James Wilkinson, Greg Parker, Martin Charlton and Jeremy Baumberg in July 2001 and is headquartered in Southampton, UK. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| IDEXX LABORATORIES, INC. | Health Technology |
| ONCOPEPTIDES AB | Health Technology |
| Aziende private | 7 |
|---|---|
Affymetrix, Inc.
 Affymetrix, Inc. Medical SpecialtiesHealth Technology Affymetrix, Inc. develops, manufactures and sells products and services for genetic analysis. The company was founded by Stephen P. A. Fodor in 1992 and is headquartered in Santa Clara, CA. | Health Technology |
Quiatech AB
Quiatech AB Pharmaceuticals: MajorHealth Technology Quiatech AB develops and manufactures drugs. It is a research based company that develops enabling technologies for genetic analysis, molecular diagnostics, and gene-based therapeutics in the expanding market of DNA technologies that offer significant improvements in the quality of DNA microarray and other DNA oligonucleotide data. It has also developed a new modified RNA chemistry (Qt RNA Technology) utilizing a novel 2 protecting group on the RNA amidites, this development greatly improves the synthesis conditions, producing fully functional RNA at high yields. It is headquartered in Uppsala, Sweden. | Health Technology |
Mesophotonics Ltd.
Mesophotonics Ltd. Computer CommunicationsElectronic Technology Mesophotonics Ltd. develops photonic crystal devices and circuits. Its devices allows light to be bent, routed and processed at sub-millimeter scale. It offers multiple optical functions and systems to be implemented on a single silicon chip for production of integrated optical devices. The company was founded by Caterina Netti, Majd Zoorob, Simon Cox, James Wilkinson, Greg Parker, Martin Charlton and Jeremy Baumberg in July 2001 and is headquartered in Southampton, UK. | Electronic Technology |
OLIGOvation AB
OLIGOvation AB Miscellaneous Commercial ServicesCommercial Services OLIGOvation AB develops enabling technologies for genetic analysis, molecular diagnostics and gene-based therapeutics. It offers services in the market of DNA technologies that offer improvements in the quality of DNA microarray and other DNA oligonucleotide data. The company was founded in February, 2000 and is headquartered in Uppsala, Sweden. | Commercial Services |
Techgen International Ltd.
Techgen International Ltd. Miscellaneous Commercial ServicesCommercial Services Techgen International Ltd. provides financial advisory services. The private company is based in London, UK. | Commercial Services |
| Oncopeptides Incentive AB | |
| Techgen Corporate Development Ltd. |
- Borsa valori
- Insiders
- Alan Hulme
